Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TAS 0612

Next Previous
Drug Profile

TAS 0612

Alternative Names: TAS-0612

Latest Information Update: 23 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Taiho Pharmaceutical
  • Class Antineoplastics
  • Mechanism of Action 70 kDa ribosomal protein S6 kinase inhibitors; Proto-oncogene protein c-akt inhibitors; Ribosomal protein S6 kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 25 Apr 2025 Pharmacodynamics and adverse events data from a preclinical study in Acute myeloid leukemia presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
  • 13 Mar 2025 Taiho Oncology terminates a phase I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA and France due to sponsor strategic decision (PO) (NCT04586270)
  • 07 Dec 2024 Pharmacodynamics data from a preclinical study in Multiple myeloma presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top